LONDON, July 11 /PRNewswire/ -- Silence Therapeutics plc (London AIM: SLN), a leading European RNA interference (RNAi) focused biotechnology company, announced today the successful opposition of a fundamental Alnylam Pharmaceuticals, Inc. European patent resulting in the patent being revoked in its entirety.
The Opposition Division of the European Patent Office, following a three day hearing, announced its decision to revoke European Patent EP 1 230 375, exclusively licensed to Alnylam Pharmaceuticals from Cancer Research Technology, Ltd (UK). The Patent, commonly referred to as the "Glover" patent, broadly relates to medicaments comprising an RNA interference mediating RNA molecule.
Opposition briefs to the Glover patent had been filed by Silence Therapeutics AG, Sanofi-Aventis Deutschland GmbH, Quark Biotech, Inc., Sirna Therapeutics, and Nucleonics, Inc. In the course of the oral hearing which lasted from July 08 to July 10, 2008, Cancer Research Technology Ltd. filed a total of seven auxiliary requests so as to defend the patent in a limited manner. None of these requests was able to overcome the concerns of the Opposition Division that the patent was legally invalid. Cancer Research Technology and Alnylam are expected to appeal the decision.
Jeff Vick, Chief Executive Officer of Silence Therapeutics, said, "The Glover patent was arguably Alnylam's broadest patent and the successful opposition represents an important victory for us in allowing us to maintain our Freedom to Operate. We have long believed that this patent would be revoked and are very pleased with the outcome. This decision by the European Patent Office further strengthens our leading position in the field of RNA interference."
Notes to Editors:
About Silence Therapeutics plc (http://www.silence-therapeutics.com)
Silence Therapeutics plc (AIM: SLN) is a leading European RNAi focused
|SOURCE Silence Therapeutics plc|
Copyright©2008 PR Newswire.
All rights reserved